

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sinco Pharmaceuticals Holdings Limited

兴科蓉医药控股有限公司

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 6833)

APPOINTMENT OF VICE CHAIRMAN OF THE BOARD AND NON-EXECUTIVE DIRECTOR

APPOINTMENT OF VICE CHAIRMAN OF THE BOARD

The board (the “**Board**”) of directors (the “**Directors**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Huang Zhijian, currently the executive Director of the Company, has been appointed the vice chairman of the Board and executive Director of the Company with effect from 24 December 2024.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The Board of Company is pleased to announce that Ms. Jing Huan (“**Ms. Jing**”), has been appointed as a non-executive Director of the Company (the “**Non-executive Director**”) with effect from 24 December 2024.

The biographical details of Ms. Jing are set out below:

Ms. Jing, aged 36, is currently the deputy general manager of the subsidiary of the Group, the Chengdu Hengmeisheng Biotechnology Co., Ltd. (成都恒美盛生物科技有限公司), mainly responsible for comprehensive management department, and assist in management of finance department, legal department, and quality department. Ms. Jing also serves as the supervisor at certain of our subsidiaries. Ms. Jing has over 10 years of experience in organizational management and human resources management, with rich experience in corporate management and team building. Since joining the group in November 2011, Ms. Jing has been mainly responsible for human resources and administrative affairs, demonstrating excellent leadership and management skills. Ms. Jing holds a Postgraduate Diploma in Organizational and Human Resource Management from the University of Hong Kong, providing her with a solid theoretical foundation and practical experience. Additionally, on January 13, 2017, Ms. Jing obtained the Certificate of Inclusion in China’s Strategic Talent Pool issued by the China Enterprise Confederation Training Center. This talent pool aims to cultivate and select high-level talents with strategic vision and global perspectives. Ms. Jing was successfully selected into this elite talent pool due to her outstanding professional abilities and extensive industry influence. Ms. Jing actively promotes corporate culture construction, committed to creating an efficient, harmonious, and innovative working environment.

Taking into consideration Ms. Jing's background, including but not limited to her gender, extensive professional experience in organizational management and human resources management, excellent skills, and profound knowledge, the Board is satisfied that Ms. Jing is of character, integrity and experience suitable for the position of a Non-executive Director. Ms. Jing's appointment will help the group better protect employees' rights, optimize internal corporate management, and provide strong support for the group's environmental, social, and governance (the "**ESG**") initiatives. Furthermore, the appointment of Ms. Jing brings valuable diversity to the Board, further enhancing the quality of decision-making and strategic vision. Following Ms. Jing's appointment, the Board has complied with the gender diversity requirement under Rule 13.92 of The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**"). Ms. Jing's professional background and leadership capabilities will inject new momentum into the Group's sustainable development and social responsibility practices, driving greater achievements in ESG.

Ms. Jing has entered into a service contract with the Company for a fixed term of one year, commencing from 24 December 2024, and shall be renewed for a further term of one year by mutual agreement between her and the Company, subject to retirement by rotation and re-election in accordance with the second amended and restated memorandum and articles of association of the Company (the "**Memorandum and Articles of Association**"). As a non-executive Director, Ms. Jing is entitled to an annual remuneration of RMB300,000 which has been determined by the Board with reference to her duties and experience and the prevailing marketing conditions.

Save as disclosed above, as at the date of this announcement, Ms. Jing (i) has not held any other directorship in any public company the securities of which are listed on any securities market in Hong Kong or overseas during the last three years preceding the date of this announcement, or any other major appointment and/or professional qualification; (ii) has no relationship with any Director, supervisor, senior management or substantial or controlling shareholders of the Company; (iii) has no other position with the Company and its subsidiaries; and (iv) has no interest in shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there is no other information required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and there are no other matters that need to be brought to the attention of the shareholders of the Company or the Stock Exchange.

The Board extends its warm welcome to Mr. Huang Zhijian and Ms. Jing on their new roles in the Company.

By order of the Board
Sinco Pharmaceuticals Holdings Limited
Huang Xiangbin
Chairman and Executive Director

Sichuan, the PRC, 24 December 2024

As at the date of this announcement, the executive Directors are Mr. Huang Xiangbin, Mr. Lei Shifeng and Mr. Huang Zhijian; the Non-executive Directors is Ms. Jing Huan; and the independent non-executive Directors are Mr. Lau Ying Kit, Mr. Wang Qing, Mr. Liu Wenfang and Mr. Bai Zhizhong.